Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Merger completion expected to be effective with market open on August 15, 2025.
  • New ticker symbol “HIND” to debut on Nasdaq Capital Market on India’s Independence Day.
  • Asset sale to Biorad Medisys also approved by ReShape shareholders.

ReShape Lifesciences® (Nasdaq: RSLS) announced shareholder approval of all proposals required to finalize its merger with Vyome Therapeutics. The merger is expected to become effective as of the commencement of trading on Friday, August 15, 2025. Following completion, the combined company will operate as Vyome Holdings, Inc., with its common stock trading on the Nasdaq Capital Market under the new symbol “HIND.”

Vyome Chairman Krishna Gupta said the new company will build a healthcare platform spanning the U.S.–India innovation corridor, with several clinical-stage assets aimed at immuno-inflammatory conditions. He noted the launch under the “HIND” ticker is timed to coincide with India’s Independence Day.

ReShape CEO Paul Hickey said the company’s shareholders also approved the sale of its assets to Biorad Medisys, adding that Vyome is positioned for success as a Nasdaq-listed company.

Maxim Group LLC advised ReShape in the transaction, with legal counsel from Fox Rothschild LLP. Chardan acted as financial advisor to Vyome, with Sichenzia Ross Ference Carmel LLP as legal counsel.